EUPRAXIA PHARMACEUTICALS INC (EPRX) Stock News

USA - Nasdaq - NASDAQ:EPRX - CA29842P1053 - Common Stock

6.23 USD

+0.1 (+1.63%)

Last: 11/26/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

EPRX Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Zacks Investment Research

Wall Street Analysts Think Eupraxia Pharmaceuticals Inc. (EPRX) Could Surge 75.08%: Read This Before Placing a Bet

15 days ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

24 days ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

2 months ago - By: Benzinga

Eupraxia Reports Encouraging Safety And Efficacy Data From Eosinophilic Esophagitis Study

2 months ago - By: Benzinga - Mentions: NBY NEOG PMI APDN ...

12 Health Care Stocks Moving In Monday's After-Market Session

7 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

News Image

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares

2 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares

3 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

4 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences

5 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis

6 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

7 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

7 months ago - By: Eupraxia Pharmaceuticals Inc. - Mentions: EPRX.CA

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

8 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

9 months ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces CFO Succession

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

a year ago - By: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million